Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 3,191 Shares

Posted by Geri Gentry on Sep 5th, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) insider Atul Dandekar sold 3,191 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $84,465.77. Following the transaction, the insider directly owned 35,559 shares of the company’s stock, valued at approximately $941,246.73. This trade represents a 8.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

On Thursday, September 3rd, Atul Dandekar sold 3,243 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $84,350.43.
On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total value of $206,850.00.
On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Trading Up 1.3%

Shares of Maze Therapeutics stock opened at $26.21 on Friday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock’s 50-day simple moving average is $28.69 and its 200 day simple moving average is $31.17.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MAZE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reiterated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and a consensus price target of $66.00.

Check Out Our Latest Analysis on MAZE

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Hedge Funds Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System lifted its stake in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its holdings in Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock valued at $247,000 after purchasing an additional 931 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Maze Therapeutics by 23.0% in the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company’s stock valued at $135,000 after purchasing an additional 977 shares during the period.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.